316 related articles for article (PubMed ID: 32227409)
21. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
22. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
Vansteenkiste JF
Future Oncol; 2014 Oct; 10(12):1925-39. PubMed ID: 24856155
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
[TBL] [Abstract][Full Text] [Related]
24. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
[TBL] [Abstract][Full Text] [Related]
26. Clinical Efficacy of Alectinib in Patients with
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
[TBL] [Abstract][Full Text] [Related]
27. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.
Della Corte CM; Barra G; Ciaramella V; Di Liello R; Vicidomini G; Zappavigna S; Luce A; Abate M; Fiorelli A; Caraglia M; Santini M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
J Exp Clin Cancer Res; 2019 Jun; 38(1):253. PubMed ID: 31196138
[TBL] [Abstract][Full Text] [Related]
30. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
[No Abstract] [Full Text] [Related]
31. Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
Schwartzberg L; Korytowsky B; Penrod JR; Zhang Y; Le TK; Batenchuk C; Krug L
Clin Lung Cancer; 2019 Jul; 20(4):287-296.e4. PubMed ID: 31130450
[TBL] [Abstract][Full Text] [Related]
32. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Pang L; Han S; Jiao Y; Jiang S; He X; Li P
Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
[TBL] [Abstract][Full Text] [Related]
33. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer.
Zhang YZ; Lai HL; Huang C; Jiang ZB; Yan HX; Wang XR; Xie C; Huang JM; Ren WK; Li JX; Zhai ZR; Yao XJ; Wu QB; Leung EL
Phytomedicine; 2024 Jun; 128():155431. PubMed ID: 38537440
[TBL] [Abstract][Full Text] [Related]
34. Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.
Dong W; Lei P; Liu X; Li Q; Cheng X
Front Immunol; 2021; 12():686057. PubMed ID: 34804000
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer.
Yoshida H; Kim YH; Ozasa H; Sakamori Y; Tsuji T; Nomizo T; Yasuda Y; Yamamoto T; Ajimizu H; Hirai T
In Vivo; 2018; 32(6):1587-1590. PubMed ID: 30348720
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
Bassanelli M; Sioletic S; Martini M; Giacinti S; Viterbo A; Staddon A; Liberati F; Ceribelli A
Anticancer Res; 2018 Jul; 38(7):3789-3796. PubMed ID: 29970498
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
[TBL] [Abstract][Full Text] [Related]
38. Dual
Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
[No Abstract] [Full Text] [Related]
39. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
[TBL] [Abstract][Full Text] [Related]
40. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
